Neovascular age-related macular degeneration (nvamd)
Clinical trials for Neovascular age-related macular degeneration (nvamd) explained in plain language.
Never miss a new study
Get alerted when new Neovascular age-related macular degeneration (nvamd) trials appear
Sign up with your email to follow new studies for Neovascular age-related macular degeneration (nvamd), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New eye injection shows promise for blinding swelling
Disease control CompletedThis early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, to see if it is safe and can help reduce swelling in the back of the eye. It includes people with three different eye conditions that cause vision loss: branch retinal vein occlusi…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD)
Phase 1/2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New antibody injection aims to tackle blinding eye diseases
Disease control CompletedThis study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD)
Phase 1/2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC